Estrogen receptor-?: Implications for the prostate gland

Chang, William Y.; Prins, Gail S.

doi:10.1002/(sici)1097-0045(19990701)40:2<115::aid-pros7>3.0.co;2-3

Cited by 113 publications

(63 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the predictor decision margin is low for most samples when their representative class is not included in training, it seems that there may be exceptions if they share a strong molecular likeness to tumors of another class (Table 2). For example, when prostate tumors are absent from the training set, prostate test samples are exclusively predicted as breast (Table 2), revealing an association of these tumors based on the commonality of hormonal regulation (41,42). Similarly, all mesothelioma samples were predicted as ovarian, perhaps reflecting their shared mesothelial cell lineage and expression of known markers such as mesothelin, retinol binding protein 1, and Wilms tumor 1 (43)(44)(45).…”

Section: Resultsmentioning

confidence: 99%

An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin

Tothill

Kowalczyk

Rischin³

et al. 2005

Cancer Research

200

144

View full text Add to dashboard Cite

Gene expression profiling offers a promising new technique for the diagnosis and prognosis of cancer. We have applied this technology to build a clinically robust site of origin classifier with the ultimate aim of applying it to determine the origin of cancer of unknown primary (CUP). A single cDNA microarray platform was used to profile 229 primary and metastatic tumors representing 14 tumor types and multiple histologic subtypes. This data set was subsequently used for training and validation of a support vector machine (SVM) classifier, demonstrating 89% accuracy using a 13-class model. Further, we show the translation of a fiveclass classifier to a quantitative PCR-based platform. Selecting 79 optimal gene markers, we generated a quantitative-PCR low-density array, allowing the assay of both fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue. Data generated using both quantitative PCR and microarray were subsequently used to train and validate a cross-platform SVM model with high prediction accuracy. Finally, we applied our SVM classifiers to 13 cases of CUP. We show that the microarray SVM classifier was capable of making high confidence predictions in 11 of 13 cases. These predictions were supported by comprehensive review of the patients' clinical histories. (Cancer Res 2005; 65(10): 4031-40)

show abstract

Section: Resultsmentioning

confidence: 99%

An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin

Tothill

Kowalczyk

Rischin³

et al. 2005

Cancer Research

200

144

View full text Add to dashboard Cite

show abstract

“…The prostate has two estrogen receptor subtypes, ER and ER (Lubahn et al, 1993;Kuiper et al, 1996). ER and ER are predominantly expressed in the prostatic stroma and epithelium, respectively (Lau et al, 1998;Prins et al, 1998;Chang and Prins, 1999). The roles of ER and ER in prostatic squamous metaplasia have been studied through use of ERKO and ERKO mice (Risbridger et al, 2001a).…”

Section: Induction Of Prostatic Squamous Metaplasia Requires Both Strmentioning

confidence: 99%

Role of stromal-epithelial interactions in hormonal responses

Cunha¹,

Cooke

Kurita

2004

Arch. Histol. Cytol.

272

191

View full text Add to dashboard Cite

show abstract

“…The traditional paradigm regarding the roles of the two ERs in the prostate is that ERB is predominantly protective, being anti-carcinogenic and pro-apoptotic (Chang & Prins 1999, Horvath et al 2001, Zhu et al 2004, McPherson et al 2010, Muthusamy et al 2011, Nakajima et al 2011, Attia & Ederveen 2012, whereas ERA is oncogenic and promotes cell proliferation and survival , Bonkhoff & Berges 2009, Celhay et al 2010, Attia & Ederveen 2012). This view is based on a range of observations including epidemiological and in vivo studies, preclinical drug trials and expression profiles of the two ERs in human prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Estrogen receptor beta in prostate cancer: friend or foe?

Nelson¹,

Tilley²,

Neal³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Prostate cancer is the commonest, non-cutaneous cancer in men. At present, there is no cure for the advanced, castration-resistant form of the disease. Estrogen has been shown to be important in prostate carcinogenesis, with evidence resulting from epidemiological, cancer cell line, human tissue and animal studies. The prostate expresses both estrogen receptor alpha (ERA) and estrogen receptor beta (ERB). Most evidence suggests that ERA mediates the harmful effects of estrogen in the prostate, whereas ERB is tumour suppressive, but trials of ERB-selective agents have not translated into improved clinical outcomes. The role of ERB in the prostate remains unclear and there is increasing evidence that isoforms of ERB may be oncogenic. Detailed study of ERB and ERB isoforms in the prostate is required to establish their cell-specific roles, in order to determine if therapies can be directed towards ERB-dependent pathways. In this review, we summarise evidence on the role of ERB in prostate cancer and highlight areas for future research.

show abstract

Estrogen receptor-?: Implications for the prostate gland

Cited by 113 publications

References 70 publications

An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin

An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin

Role of stromal-epithelial interactions in hormonal responses

Estrogen receptor beta in prostate cancer: friend or foe?

Contact Info

Product

Resources

About